BACKGROUND: Traumatic brain injuries (TBI) are associated with complex inflammatory pathways that lead to the development of secondary injuries such as cerebral ischaemia, elevated intracranial pressure and cognitive deficits. The association between intracellular danger signalling involving nuclear chromatin-binding factor, high mobility group box-1 (HMGB1) and inflammatory pathways following TBI has not yet been fully understood. PRIMARY OBJECTIVE: To comprehensively review the available literature regarding the potential diagnostic, prognostic and therapeutic use of HMGB1 in TBI. METHODS: A systematic literature review of studies available in PubMed using human and animal subjects was performed. A total of eight studies were included in the results. CONCLUSIONS: A comprehensive review of these reports demonstrated that, following TBI, HMGB1 is released from damaged neurons and is elevated in patient's serum and CSF. Furthermore, these studies showed the potential for HMGB1 to serve as a prognostic biomarker and therapeutic target in patients with TBI. Thus, HMGB1 is a prospective candidate for future studies as it shows promise in treating and/or predicting the sequelae of TBI.
BACKGROUND:Traumatic brain injuries (TBI) are associated with complex inflammatory pathways that lead to the development of secondary injuries such as cerebral ischaemia, elevated intracranial pressure and cognitive deficits. The association between intracellular danger signalling involving nuclear chromatin-binding factor, high mobility group box-1 (HMGB1) and inflammatory pathways following TBI has not yet been fully understood. PRIMARY OBJECTIVE: To comprehensively review the available literature regarding the potential diagnostic, prognostic and therapeutic use of HMGB1 in TBI. METHODS: A systematic literature review of studies available in PubMed using human and animal subjects was performed. A total of eight studies were included in the results. CONCLUSIONS: A comprehensive review of these reports demonstrated that, following TBI, HMGB1 is released from damaged neurons and is elevated in patient's serum and CSF. Furthermore, these studies showed the potential for HMGB1 to serve as a prognostic biomarker and therapeutic target in patients with TBI. Thus, HMGB1 is a prospective candidate for future studies as it shows promise in treating and/or predicting the sequelae of TBI.
Authors: Setthasorn Zhi Yang Ooi; Robert James Spencer; Megan Hodgson; Samay Mehta; Nicholas Lloyd Phillips; Gwilym Preest; Susruta Manivannan; Matt P Wise; James Galea; Malik Zaben Journal: Neurosurg Rev Date: 2022-07-06 Impact factor: 2.800
Authors: Joon Yong Chung; Nicolas Krapp; Limin Wu; Sevda Lule; Lauren M McAllister; William J Edmiston; Samantha Martin; Emily Levy; Tanya Songtachalert; John S Sherwood; Erin M Buckley; Bharat Sanders; Saef Izzy; Suzanne Hickman; Shuzhen Guo; Josephine Lok; Joseph El Khoury; Eng H Lo; David Kaplan; Michael J Whalen Journal: J Neurotrauma Date: 2018-08-03 Impact factor: 5.269
Authors: Teodor T Postolache; Abhishek Wadhawan; Adem Can; Christopher A Lowry; Margaret Woodbury; Hina Makkar; Andrew J Hoisington; Alison J Scott; Eileen Potocki; Michael E Benros; John W Stiller Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Verena Peek; Lois M Harden; Jelena Damm; Ferial Aslani; Stephan Leisengang; Joachim Roth; Rüdiger Gerstberger; Marita Meurer; Maren von Köckritz-Blickwede; Sabine Schulz; Bernhard Spengler; Christoph Rummel Journal: Pharmaceuticals (Basel) Date: 2021-06-11
Authors: Pavel Klein; Raymond Dingledine; Eleonora Aronica; Christophe Bernard; Ingmar Blümcke; Detlev Boison; Martin J Brodie; Amy R Brooks-Kayal; Jerome Engel; Patrick A Forcelli; Lawrence J Hirsch; Rafal M Kaminski; Henrik Klitgaard; Katja Kobow; Daniel H Lowenstein; Phillip L Pearl; Asla Pitkänen; Noora Puhakka; Michael A Rogawski; Dieter Schmidt; Matti Sillanpää; Robert S Sloviter; Christian Steinhäuser; Annamaria Vezzani; Matthew C Walker; Wolfgang Löscher Journal: Epilepsia Date: 2017-12-15 Impact factor: 5.864